Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
Sponsor: HC Biopharma Inc.
Summary
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary objectives of study are as follows: To estimate the PK parameters of single-ascending SC doses of HC022 in healthy subjects;To evaluate the immunogenicity of HC022 administered to healthy subjects.
Official title: A Phase Ia Single Center, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Doses of HC022 in Healthy Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
38
Start Date
2024-11-25
Completion Date
2026-01-08
Last Updated
2025-04-17
Healthy Volunteers
Yes
Conditions
Interventions
HC022
Administered as specified in the treatment arm
Placebo
Administered as specified in the treatment arm
Locations (3)
Peking Union Medical College Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
The Clinical Pharmacology Research Center of PUMCH
Beijing, China